A 62-year-old man with hypertension and dyslipidaemia is found to have an eGFR of 52 mL/min/1.73 m² and a urine albumin-creatinine ratio of 35 mg/mmol on two occasions. He is not diabetic. According to Australian CKD guidance, what is the most appropriate first-line pharmacological intervention to slow kidney disease progression and reduce cardiovascular risk?